Insta
US Green Signals Four Candidate COVID-19 Vaccines For Clinical Trials; Six More Under Review
US President Donald Trump (Pic Via Twitter)
In a major positive development for the global fight against COVID-19, the United States (US) has approved four candidate vaccines for taking up clinical trials, while six more are in the pipeline to reaching that stage and are currently under review, reports news agency ANI.
The development was announced by US' Food and Drug Administration (FDA)'s head Stephen Hahn.
It comes as a major boost for the US Government's Operation Warp Speed which is a joint project between the Government's Health and Defence Departments to deliver 300 million doses of a vaccine for the viral disease by January 2021. The Operation had been launched in May.
However, it should also be noted that on Tuesday (30 June), US' top physician and immunologist Dr Anthony Fauci warned that there was no certainty that the US will be able to develop a safe and effective vaccine against COVID-19.
Dr Fauci also said that the data on the effectiveness of different potential vaccines may become available in the winters or early next year.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
